Furthermore, we observed a stepwise increase in cardiovascular and renal risk among individuals with CKM-MAFLD than those with CKM-non-MAFLD, supporting the idea that the liver is an active participant in systemic metabolic disease rather than a passive bystander [14, 15]. The gene discussed is CKM; the disease is metabolic disease.